(NASDAQ: MRNA) Moderna's forecast annual revenue growth rate of 14.57% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 45.92%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.25%.
Moderna's revenue in 2026 is $1,944,000,000.On average, 27 Wall Street analysts forecast MRNA's revenue for 2026 to be $831,347,487,520, with the lowest MRNA revenue forecast at $697,857,962,208, and the highest MRNA revenue forecast at $929,292,464,672. On average, 26 Wall Street analysts forecast MRNA's revenue for 2027 to be $968,786,407,072, with the lowest MRNA revenue forecast at $701,807,356,448, and the highest MRNA revenue forecast at $1,417,832,532,160.
In 2028, MRNA is forecast to generate $1,167,440,937,344 in revenue, with the lowest revenue forecast at $850,304,579,872 and the highest revenue forecast at $1,446,663,110,112.